Search results for: Medication

Collection of CQUIN CCG2 indicator performance data from 1st April 2022 - appropriate antibiotic prescribing for UTI in adults ages 16 and over (F22-6943)

Requested: 01 April 2022. GRANTED (ALL)

Treatment of metastatic non-small cell lung cancer (F22-6942)

Requested: 01 April 2022. GRANTED (PART), NOT HELD (PART)

Treatment of Metastatic/advanced Breast cancer (F22-6941)

Requested: 01 April 2022. GRANTED (PART), NOT HELD (PART)

Number of commercial clinical trials in 2021 (F22-6804)

Requested: 07 March 2022. GRANTED (ALL)

Use of Emicizumab for the treatment of Haemophilia A (F22-6785)

Requested: 01 March 2022. GRANTED (ALL)

Use of iron therapy treatment (F22-6626)

Requested: 28 January 2022. GRANTED (ALL)

Usage of biologic medication by the Dermatology and Rheumatology departments (F22-6608)

Requested: 26 January 2022. GRANTED (ALL)

Warm homes grants (F22-6604)

Requested: 25 January 2022. GRANTED (PART), NOT HELD (PART)

Usage of intra-vitreal injections or implants (F22-6590)

Requested: 24 January 2022. GRANTED (ALL)

Number of immunoglobulin vials used from October - December 2021 (F22-6581)

Requested: 21 January 2022. GRANTED (ALL)

Biologic and Biosimilar product prescribing in Rheumatology (F21-6534)

Requested: 12 January 2022. GRANTED (ALL)

Treatment with Ofatumumab (F21-6442)

Requested: 20 December 2021. NOT HELD (ALL)

Haemophilia A (F21-6392)

Requested: 09 December 2021. GRANTED (ALL)

Treatment of fungal infections (F21-6278)

Requested: 16 November 2021. GRANTED (ALL)

Biologic medications in gastroenterology (F21-6272)

Requested: 15 November 2021. GRANTED (ALL)

Prescriptions for Solifenacin and Tovias (F21-6263)

Requested: 11 November 2021. GRANTED (ALL)

Biologic products in respiratory medicine (F21-6126)

Requested: 14 October 2021. GRANTED (ALL)

Guidance on the Management of Direct Oral Anti-Coagulant (DOAC) (F21-6106)

Requested: 12 October 2021. GRANTED (ALL)

Anti-VEFG treatments for eye conditions (F21-6019)

Requested: 27 September 2021. GRANTED (PART), NOT HELD (PART)

Dermatological and rheumatological conditions (F21-6018)

Requested: 27 September 2021. GRANTED (ALL)

Dermatology drugs (F21-5966)

Requested: 17 September 2021. GRANTED (ALL)

Analysing the treatment of neurology patients (F21-5952)

Requested: 15 September 2021. GRANTED (PART), NOT HELD (PART)

Medication for health conditions (F21-5943)

Requested: 14 September 2021. GRANTED (ALL)

Intravenous administration of high dose vitamin C to critically ill patients (F21-5926)

Requested: 12 September 2021. GRANTED (ALL)

Biologics drugs (F21-5920)

Requested: 10 September 2021. GRANTED (ALL)

Biologic and biosimilar products within Rheumatology (F21-5886)

Requested: 06 September 2021. GRANTED (PART), NOT HELD (PART)

Biologic products in respiratory medicine (F21-5857)

Requested: 01 September 2021. GRANTED (ALL)

Possible haemophilia treatments (F21-5841)

Requested: 27 August 2021. GRANTED (ALL)

Pharmacological Management of Chronic Kidney Disease (F21-5828)

Requested: 25 August 2021. GRANTED (ALL)

monoclonal antibodies for covid-19 (F21-5807)

Requested: 22 August 2021. NOT HELD (ALL)

trust spending on unlicensed medicines (F21-5784)

Requested: 18 August 2021. GRANTED (PART), NOT HELD (PART)

Growth Hormone & Spasticity (F21-5766)

Requested: 13 August 2021. GRANTED (ALL)

Number of COVID-19 vaccines administered, wasted and disposed of (F21-5719)

Requested: 04 August 2021. GRANTED (ALL)

Treatment of Multiple Sclerosis, Stroke, Spinal or brain trauma (F21-5655)

Requested: 23 July 2021. GRANTED (ALL)

Chronic Kidney Disease (F21-5631)

Requested: 19 July 2021. GRANTED (ALL)

Medication used for melanoma and renal cell carcinoma (F21-5425)

Requested: 16 June 2021. GRANTED (PART), NOT HELD (PART)

Initiations for Atezolizumab (TA666) with bevacizumab (Avastin) for treating advanced/unresectable hepatocellular carcinoma (F21-5341)

Requested: 04 June 2021. NOT HELD (ALL)

Incidence and treatment of breast cancer (F21-5316)

Requested: 01 June 2021. GRANTED (PART), NOT HELD (PART)

Anti-VEFG treatments for eye conditions (F21-5210)

Requested: 13 May 2021. GRANTED (PART), NOT HELD (PART)

Biologic and Biosimilar product prescribing in Dermatology/Rheumatology (F21-5175)

Requested: 10 May 2021. GRANTED (ALL)

Use of biologic drugs by the Dermatology and Gastroenterology departments (F21-5164)

Requested: 07 May 2021. GRANTED (PART), NOT HELD (PART)

Usage of antibiotics (F21-5134)

Requested: 04 May 2021. GRANTED (ALL)

Medication used to treat multiple sclerosis and migraines (F21-5119)

Requested: 30 April 2021. ADVICE/ASSISTANCE, GRANTED (PART), LINKS PROVIDED, NOT HELD (PART)

Incidence and treatment of prostate cancer and myelofibrosis (F21-5082)

Requested: 26 April 2021. GRANTED (PART), NOT HELD (PART)

Use of medication and treatment of Haemophilia B and Von Willebrand Disease (F21-5018)

Requested: 16 April 2021. GRANTED (PART), NOT HELD (PART)

Incidence and treatment of Haemophilia A (F21-5005)

Requested: 14 April 2021. GRANTED (ALL)

Use of biologic drugs within the last six months of 23rd February 2021 (F21-4728)

Requested: 23 February 2021. GRANTED (ALL)

Amount of Human Serum Albumin purchased (F21-4715)

Requested: 22 February 2021. GRANTED (PART)

Medication used to treat colorectal cancer (F21-4717)

Requested: 22 February 2021. GRANTED (ALL)

Weighing devices and incidents concerning vancomycin, gentamicin and alteplase (F21-4712)

Requested: 21 February 2021. GRANTED (PART), NOT HELD (PART)

Use of medication to treat clotting disorders (F21-4687)

Requested: 16 February 2021. GRANTED (ALL)

Authorised vehicles only places (F21-4679)

Requested: 15 February 2021. GRANTED (ALL)

Paediatric usage of Buccolam for pre-med/diagnostic use (F21-4615)

Requested: 04 February 2021. GRANTED (PART), NOT HELD (PART)

Medication/drug wastage and total expenditure (F21-4595)

Requested: 02 February 2021. ADVICE/ASSISTANCE, GRANTED (PART), LINKS PROVIDED, REFUSED (PART)

Use of biologic drugs by the Dermatology and Gastroenterology departments (F21-4566)

Requested: 28 January 2021. GRANTED (PART), NOT HELD (PART)

Biologics and Biosimilar prescribing (F21-4525)

Requested: 21 January 2021. GRANTED (PART), NOT HELD (PART)

Usage of bevacizumab and treatment of Haemophilia B (F21-4506)

Requested: 18 January 2021. GRANTED (ALL)

Use of biologics and asthma treatment (F21-4457)

Requested: 11 January 2021. GRANTED (PART), NOT HELD (PART)

Usage of liquid oxygen (F20-4326)

Requested: 05 December 2020. GRANTED (ALL)

Errors in Medication [IC-80950-L2B0] (F20-4298)

Requested: 30 November 2020. GRANTED (ALL)

Ketamine-related hospitalisations of under 25s (F20-4248)

Requested: 20 November 2020. GRANTED (ALL)

Use of growth hormone and acromegaly (F20-4247)

Requested: 20 November 2020. GRANTED (ALL)

Number of patients treated with specified medication in the past six months (F20-4023)

Requested: 30 September 2020. GRANTED (PART), NOT HELD (PART)

Aciclovir powder for intravenous infusion (F20-3434)

Requested: 08 April 2020. GRANTED (PART), NOT HELD (PART)

Treatment for female patients over the age of 50 with osteoporosis (F20-3400)

Requested: 30 March 2020. GRANTED (ALL)

Unlicensed Cannabis-Based Products for Medicinal Use (F20-3341)

Requested: 09 March 2020. NOT HELD (ALL)

Prescribing in Ophthalmology (F20-3301)

Requested: 25 February 2020. GRANTED (ALL)

cutaneous squamous cell carcinoma / multiple myeloma /chronic lymphocytic leukaemia (F20-3271)

Requested: 14 February 2020. GRANTED (PART), NOT HELD (PART)

Entyvio (vedolizumab) treatment for Ulcerative Colitis and Crohn's Disease (F20-3265)

Requested: 13 February 2020. GRANTED (ALL)

Adalimumab (F20-3262)

Requested: 11 February 2020. GRANTED (ALL)

Multiple Sclerosis treatments (F20-3237)

Requested: 05 February 2020. GRANTED (ALL)

Iron Infusions and Patient Product Breakdown (F20-3230)

Requested: 03 February 2020. GRANTED (ALL)

Dermatology Biologics (F20-3202)

Requested: 27 January 2020. GRANTED (ALL)

Medication for Crohn's Disease and Ulcerative Colitis for October and December 2019 (F20-3168)

Requested: 16 January 2020. GRANTED (ALL)

Lung cancer and Melanoma drug treatments (F19-3106)

Requested: 20 December 2019. GRANTED (PART), NOT HELD (PART)

Growth Hormone treatments (F19-3058)

Requested: 05 December 2019. GRANTED (ALL)

Outpatient Pharmacy Service (F19-3100)

Requested: 28 November 2019. GRANTED (ALL)

In-patient Vitamin K Antagonists dosing/VTE risk assessment practices (F19-3038)

Requested: 28 November 2019. GRANTED (ALL)

Wholesale Distribution Authorisation (for medicines for human use) licence (F19-3026)

Requested: 21 November 2019. GRANTED (ALL)